O	0	12	Pathological
O	13	21	complete
O	22	30	response
O	31	36	rates
O	37	46	comparing
O	47	48	3
O	49	55	versus
O	56	57	6
O	58	64	cycles
O	65	67	of
B-intervention	68	82	epidoxorubicin
I-intervention	83	86	and
I-intervention	87	96	docetaxel
O	97	99	in
O	100	103	the
O	104	115	neoadjuvant
O	116	123	setting
O	124	126	of
O	127	135	patients
O	136	140	with
O	141	146	stage
O	147	149	II
O	150	153	and
O	154	157	III
O	158	164	breast
O	165	171	cancer
O	171	172	.

O	173	175	We
O	176	185	conducted
O	186	187	a
O	188	199	prospective
O	200	210	randomized
O	211	216	study
O	217	219	to
O	220	227	compare
O	228	231	the
O	232	239	results
O	240	242	of
O	243	244	3
O	245	251	cycles
O	252	254	of
O	255	269	epidoxorubicin
O	269	270	/
O	270	279	docetaxel
O	280	282	to
B-control	283	284	6
I-control	285	291	cycles
I-control	292	294	of
I-control	295	309	epidoxorubicin
I-control	309	310	/
I-control	310	319	docetaxel
O	320	325	prior
O	326	328	to
O	329	336	surgery
O	337	339	in
O	340	346	breast
O	347	353	cancer
O	354	362	patients
O	363	367	with
O	368	376	clinical
O	377	383	stages
O	384	386	II
O	387	390	and
O	391	394	III
O	394	395	.

B-total-participants	396	401	Forty
I-total-participants	401	402	-
I-total-participants	402	406	five
B-eligibility	407	415	patients
I-eligibility	416	424	eligible
I-eligibility	425	428	for
I-eligibility	429	440	neoadjuvant
I-eligibility	441	453	chemotherapy
O	454	458	were
O	459	467	randomly
O	468	476	assigned
O	477	479	to
O	480	487	receive
O	488	494	either
O	495	496	3
O	497	498	(
O	498	503	group
O	504	505	1
O	505	506	)
O	507	509	or
O	510	511	6
O	512	513	(
O	513	518	group
O	519	520	2
O	520	521	)
O	522	528	cycles
O	529	531	of
O	532	546	epidoxorubicin
O	546	547	/
O	547	556	docetaxel
O	557	562	prior
O	563	565	to
O	566	573	surgery
O	573	574	.

O	575	587	Chemotherapy
O	588	597	consisted
O	598	600	of
O	601	615	epidoxorubicin
O	616	618	75
O	619	621	mg
O	621	622	/
O	622	623	m
O	624	627	and
O	628	637	docetaxel
O	638	640	75
O	641	643	mg
O	643	644	/
O	644	645	m
O	646	648	on
O	649	652	day
O	653	654	1
O	655	657	in
O	658	659	3
O	659	660	-
O	660	664	week
O	665	671	cycles
O	671	672	.

O	673	676	The
O	677	684	primary
O	685	693	endpoint
O	694	697	was
O	698	701	the
B-outcome-Measure	702	714	pathological
I-outcome-Measure	715	723	complete
I-outcome-Measure	724	732	response
I-outcome-Measure	733	734	(
I-outcome-Measure	734	737	pCR
I-outcome-Measure	737	738	)
I-outcome-Measure	739	743	rate
O	743	744	;
O	745	754	secondary
O	755	764	endpoints
O	765	769	were
O	770	773	the
B-outcome-Measure	774	779	rates
I-outcome-Measure	780	782	of
I-outcome-Measure	783	789	breast
I-outcome-Measure	789	790	-
I-outcome-Measure	790	800	conserving
I-outcome-Measure	801	808	surgery
O	809	812	and
O	813	816	the
B-outcome-Measure	817	825	axillary
I-outcome-Measure	826	831	lymph
I-outcome-Measure	832	836	node
I-outcome-Measure	837	843	status
O	844	846	in
O	847	851	both
O	852	858	groups
O	858	859	.

O	860	861	A
B-outcome	862	865	pCR
O	866	874	occurred
O	875	877	in
B-iv-bin-percent	878	880	10
I-iv-bin-percent	880	881	%
O	882	883	(
B-iv-bin-abs	883	886	two
O	887	889	of
B-intervention-participants	890	892	20
O	892	893	)
O	894	896	in
O	897	902	Group
O	903	904	1
O	905	908	and
O	909	911	in
B-cv-bin-percent	912	914	36
I-cv-bin-percent	914	915	%
O	916	917	(
B-cv-bin-abs	917	921	nine
O	922	924	of
B-control-participants	925	927	25
O	927	928	)
O	929	931	in
O	932	937	Group
O	938	939	2
O	939	940	,
O	941	946	which
O	947	950	was
O	951	964	statistically
O	965	976	significant
O	977	978	(
O	978	979	p
O	979	980	=
O	980	981	0
O	981	982	.
O	982	985	045
O	985	986	)
O	986	987	.

B-outcome	988	994	Breast
I-outcome	994	995	-
I-outcome	995	1005	conserving
I-outcome	1006	1013	surgery
I-outcome	1014	1019	could
I-outcome	1020	1022	be
I-outcome	1023	1032	performed
O	1033	1035	in
B-iv-bin-percent	1036	1038	70
I-iv-bin-percent	1038	1039	%
O	1040	1041	(
B-iv-bin-abs	1041	1043	14
O	1044	1046	of
B-intervention-participants	1047	1049	20
O	1049	1050	)
O	1051	1053	in
O	1054	1059	Group
O	1060	1061	1
O	1062	1065	and
O	1066	1068	in
B-cv-bin-percent	1069	1071	76
I-cv-bin-percent	1071	1072	%
O	1073	1074	(
B-cv-bin-abs	1074	1076	19
O	1077	1079	of
B-control-participants	1080	1082	25
O	1082	1083	)
O	1084	1086	in
O	1087	1092	Group
O	1093	1094	2
O	1095	1096	(
O	1096	1097	p
O	1097	1098	=
O	1098	1099	0
O	1099	1100	.
O	1100	1103	065
O	1103	1104	)
O	1104	1105	.

B-outcome	1106	1114	Axillary
I-outcome	1115	1120	lymph
I-outcome	1121	1125	node
I-outcome	1126	1132	status
I-outcome	1133	1136	was
I-outcome	1137	1145	negative
O	1146	1148	in
B-iv-bin-percent	1149	1151	45
I-iv-bin-percent	1151	1152	%
O	1153	1154	(
B-iv-bin-abs	1154	1158	nine
O	1159	1161	of
B-intervention-participants	1162	1164	20
O	1164	1165	)
O	1166	1168	in
O	1169	1174	Group
O	1175	1176	1
O	1177	1180	and
B-cv-bin-percent	1181	1183	52
I-cv-bin-percent	1183	1184	%
O	1185	1186	(
B-cv-bin-abs	1186	1188	13
O	1189	1191	of
B-control-participants	1192	1194	25
O	1194	1195	)
O	1196	1198	in
O	1199	1204	Group
O	1205	1206	2
O	1207	1208	(
O	1208	1209	p
O	1209	1210	=
O	1210	1211	0
O	1211	1212	.
O	1212	1214	86
O	1214	1215	)
O	1215	1216	.

O	1217	1219	We
O	1220	1228	conclude
O	1229	1233	that
O	1234	1235	6
O	1236	1242	cycles
O	1243	1245	of
O	1246	1249	pre
O	1249	1250	-
O	1250	1259	operative
O	1260	1274	epidoxorubicin
O	1274	1275	/
O	1275	1284	docetaxel
O	1285	1291	versus
O	1292	1293	3
O	1294	1300	cycles
O	1301	1303	of
O	1304	1307	pre
O	1307	1308	-
O	1308	1317	operative
O	1318	1332	epidoxorubicin
O	1332	1333	/
O	1333	1342	docetaxel
O	1343	1356	significantly
O	1357	1366	increases
O	1367	1370	the
O	1371	1374	pCR
O	1375	1380	rates
O	1381	1384	for
O	1385	1391	breast
O	1392	1398	cancer
O	1399	1407	patients
O	1407	1408	.
